Towards commercial allogeneic cell therapy manufacturing

In by

Spotlight Article

Interview

Maria Del Pilar Redondo

Strategies for scale-up and scale-out

MARIA DEl PILAR REDONDO holds an MsC in Pharmacy, specializing in Pharmaceutical technology and analysis and control of drugs. Although she began her career at Pfizer within the area of Quality, she later focused on Pharmaceutical Development. After incorporation into the Pharmamar group in 2005, she became in charge of pharmaceutical development and production of investigational medicines for the treatment of Alzheimer’s disease. Pilar joined Tigenix SAU in June 2013 as Senior Director of Technical Operations. Her responsibilities included the overview and management of activities in the areas of Pharmaceutical Development (CMC/Industrialization) and Manufacturing of the stem cell platform.

DOI:10.18609/cgti.2018.114

Citation: Cell Gene Therapy Insights 2018; 4(11), 1153-1156
Open access

This content is restricted to registered users. Click here to Register or Login here.